非布司他治疗痛风性关节炎的疗效及其安全性评价

doi:10.13481/j.1671-587x.20170127

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (01): 135-140.doi: 10.13481/j.1671-587x.20170127

非布司他治疗痛风性关节炎的疗效及其安全性评价

鄢海波, 马宁, 崔春丽, 刘涛, 赵令, 姜振宇

吉林大学第一医院风湿免疫科, 吉林长春 130021

收稿日期:2016-06-03 出版日期:2017-01-28 发布日期:2017-02-08
通讯作者: 姜振宇,教授,博士研究生导师(Tel:0431-88782060,E-mail:jlujzy@aliyun.com.cn) E-mail:jlujzy@aliyun.com.cn
作者简介:鄢海波(1990-),女,黑龙江省鹤岗市人,医师,在读医学硕士,主要从事风湿免疫性疾病的临床及基础方面的研究。
基金资助:
吉林省科技厅科技发展计划项目资助课题（20150101152JC）

Curative effect of febuxostat in treatment of gouty arthritis and its safety evaluation

YAN Haibo, MA Ning, CUI Chunli, LIU Tao, ZHAO Ling, JIANG Zhenyu

Department of Rheumatologyand Immunology, First Hospital, Jilin University, Changchun 130021, China

Received:2016-06-03 Online:2017-01-28 Published:2017-02-08

摘要/Abstract

摘要：

目的：观察非布司他治疗痛风性关节炎的疗效及治疗前后患者受累关节彩色超声图像的变化。方法：选择66例男性痛风性关节炎患者，根据药物使用情况分为非布司他组（非布司他40 mg·d^-1，n=37）和别嘌醇组（别嘌醇100 mg·d^-1，n=29），观察2组患者治疗前后血尿酸（UA）、血脂水平和滑膜周围血流信号及受累关节的彩色多普勒超声图像的变化。结果：2组患者治疗后血UA水平下降，与治疗前比较差异均有统计学意义（P<0.05）；在16、20和24周，非布司他组患者达到目标血UA值的百分率均较别嘌醇组高，2组间比较差异有统计学意义（P<0.05）。与治疗前比较，治疗后非布司他组患者高密度脂蛋白（HDL）水平明显升高（P=0.001），而总胆固醇（TC）、甘油三酯（TG）及低密度脂蛋白（LDL）水平无明显变化（P>0.05）；别嘌醇组患者治疗前后TC、HDL、LDL和TG水平均无明显变化（P>0.05）。2组患者治疗后大部分痛风结晶消失（非布司他组占71.4%，别嘌醇组占58.9%），非布司他组较别嘌醇组痛风结晶溶解效果更佳。2组患者痛风急性发作期的关节腔积液、关节周围软组织肿胀和滑膜周围血流信号均有改善，但2组之间比较未见明显差别。2组患者痛风慢性发作期表现比较无明显差异。结论：非布司他可更有效地降低痛风性关节炎患者血UA水平，改善痛风急性发作期表现，痛风结晶溶解效果更佳。

关键词: 彩色多普勒超声, 非布司他, 痛风性关节炎

Abstract:

Objective: To observe the efficacy of febuxostat in the treatment of gouty arthritis and the changes of ultrasound image of the affected joints before and after treatment.Methods: Sixty-six patients with gouty arthritis were selected and divided into febuxostat group(febuxostat 40 mg·d^-1,n=37) and allopurinol group(allopurinol 100 mg·d^-1,n=29) according to the situation of drugs.The serum uric acid(UA),lipid levels of the subjects in two groups and the changes of synovial membrane surrounding blood flows signals and ultrasound images of the affected joints before and after treatment were observed.Results: Compared with before treatment,the UA levels of patients in two groups were decreased after treatment(P<0.05);At 16,20,24 weeks, the percentages of the patients whose serum UA level reached the target value in febuxostat group was higher than that of the patients in allopurinol group(P<0.05).Compared with before treatment,the level of high density lipoprotein(HDL) in febuxostat group after treatment was increased(P=0.001);the levels of triglyceride(TG),total cholesterol(TC) and low density lipoprotein(LDL) had no significant changes(P>0.05).There were no statistically significant differences of TC,TG,LDL and HDL of the patients in allopurinol group between before and after treatment(P>0.05). Most of the UA crystal disappeared after treatment of the patients in two groups (febuxostat group 71.4%, allopurinol group 58.9%);febuxostat was better than allopurinol in dissolving UA crystal with acute gout attack.The articular effusion at acute stage of gout,joint soft tissue swelling and synovial membrane surrounding blood flow signals of the patients in two groups were improved,but there were no notably changes between two groups.There were no significant changes in chronic gout attack of the patients in two groups.Conclusion: Febuxostat can effectively reduce the UA levels of the patients with gouty arthritic, improve the performance of acute gout attack, and effectively dissolve the crystal.

Key words: febuxostat, color Doppler ultrasound, gouty arthritis

中图分类号:

R589.7

鄢海波, 马宁, 崔春丽, 刘涛, 赵令, 姜振宇. 非布司他治疗痛风性关节炎的疗效及其安全性评价[J]. 吉林大学学报(医学版), 2017, 43(01): 135-140.

YAN Haibo, MA Ning, CUI Chunli, LIU Tao, ZHAO Ling, JIANG Zhenyu. Curative effect of febuxostat in treatment of gouty arthritis and its safety evaluation[J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 135-140.

参考文献

[1] 康秀民.彩色多普勒超声在膝关节滑膜炎诊断中的价值[J].航空航天医学杂志,2014,25(10):1387-1388.
[2] 何丹青,王玲,陈捷.痛风性关节炎患者受累关节的彩色多普勒超声图像特点[J].山东医药,2015,55(11):53-54.
[3] 伍业冬,吴雅菲,李坚,等.彩色多普勒超声对痛风性关节炎的早期临床诊断价值研究[J].内科,2015,10(4):474-476.
[4] Fodor D,Nestorova R,Vlad V,et al.The place of musculoskeletal ultrasonography in gout diagnosis[J].Med Ultrason,2014,16(4):336-344.
[5] 沈赟,金星,陶沙.不同剂量非布司他与别嘌呤醇对高尿酸血症伴痛风患者可溶性细胞间黏附分子1影响的对比观察[J].中国全科医学,2014,17(14):1665-1667.
[6] 张玉秋.治疗高尿酸血症致慢性痛风的新药非布司他[J].中国药物与临床,2011,11(12):1406-1407.
[7] Schueller-Weidekamm C,Schueller G,Aringer M, et al.Impact of sonography in gouty arthritis:Comparison with conventional radiography, clinical examination,and laboratory findings[J].Eur J Radiol,2007, 62(3):437-443.
[8] Dufauret-Lombard C,Vergne-Salle P,Simon A,et al.Ultrasonography in chondrocalcinosis[J].Joint Bone Spine,2010,77(3):218-221.
[9] Dalbeth N,Doyle AJ.Imaging of gout:an overview[J].Best Pract Res Clin Rheumatol,2012,26(6):823-838.
[10] Ye P,Yang S,Zhang WL,et al.Efficacy and tolerability of febuxostat in hyperuricemic[J].Clin Therap,2013,35(2):180-189.
[11] Gaffo AL,Saag KG.Febuxostat the evidence for its use in the treatment of hyperuriciamia and gout[J].Division Clin Immunol Rheumatol, 2009,4:25-36.
[12] Becker MA,Ralph Schumacher H,Wortmann RL,et al.Febuxostat compated with allopurinol in patients with hyperuricemia and gout[J].N Engl J Med,2005,353:2450-2461.
[13] Huang XF,Du H.An allopurinol-controlled,multicenter,randomized,doublebind,parallel between-group,comparative study of febuxostat in Chinese patients with gout and hyperuricemia[J].Int J Rheum Dis,2014,17(6):679-686.
[14] Ottaviani S,Bardin T,Richette P.Usefulness of ultrasonography for gout[J].Joint Bone Spine,2012,79(5):441-445.
[15] Fodor D,Albu A,Gherman C.Crystal-associated synovitis-ultrasonographic feature and clinical correlation[J].Ortop Traumatol Rehabil, 2008,10(2):99-110.
[16] Thiele RG,Schlesinger N.Ultrasonography shows disappearance of monosodiumurate crytal deposition on hyaline carilage after sustained normouricemia is achieved[J].Rheumatol Int,2010,30(4):495-503.
[17] Codreanu C,Enache L.Is ultrasound changing the way we understand rheumatology?Including ultrasound examination in the classification criteria of polymyalgia rheumatica and gout[J].Med Ultrasonogr,2015,17(1):97-103.

非布司他治疗痛风性关节炎的疗效及其安全性评价

Curative effect of febuxostat in treatment of gouty arthritis and its safety evaluation

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

Metrics

本文评价

推荐阅读 0

[1]	戴惠咛, 吕帅, 王德利, 李丹, 张师桃, 刘嘉凝, 刘阳, 刘小波, 李婉南. 葵花盘粉有效成分对小鼠高尿酸血症的治疗作用[J]. 吉林大学学报(医学版), 2018, 44(02): 327-331.
[2]	樊海瑞, 赵岩, 傅警龙, 张海波, 王德超, 郜玉钢, 张连学. 痛风宁胶囊对大鼠急性痛风性关节炎的抗炎作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(02): 270-274.
[3]	李丽芳, 叶真. 孕11~40周正常胎儿静脉导管血流频谱变化规律及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(01): 186-189.
[4]	赵朋, 付彤, 张秀祥, 战越, 关欣, 石爱平. 乳腺癌伴甲状腺癌和皮肌炎1例报告及3种疾病关联性文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1015-1018.
[5]	张进, 刘涛, 姜振宇, 鄢海波, 张彦东. 痛风患者血尿酸与血脂水平的关系及非布司他的降血脂作用[J]. 吉林大学学报(医学版), 2015, 41(05): 1018-1022.
[6]	陈恩琪\|刘美含\|石卫东\|姜微\|张丽丽 \|张冬梅\|林昱. 彩色多普勒超声评价下肢动脉缺血性疾病侧支动脉建立的价值[J]. J4, 2011, 37(3): 548-551.
[7]	张冬梅, 刘美含, 石卫东, 陈恩琪, 李新颖, 林昱. 下肢动脉硬化闭塞症的彩色多普勒超声整体分级与临床分期的相关性分析[J]. J4, 2010, 36(5): 982-985.
[8]	石卫东, 刘美含, 李新颖, 陈恩琪, 陈丽波, 尹帅. 动脉硬化闭塞症的彩色多普勒超声分级与ET和NO的关联性分析[J]. J4, 2009, 35(4): 738-741.
[9]	石卫东，李新颖，苑晶慧，张丽丽，宋军，伊莲花，孙志霞. TCD与彩色多普勒超声联合应用诊断锁骨下动脉盗血综合征[J]. J4, 2006, 32(6): 1103-1105.